Overview

Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer

Status:
Unknown status

Trial end date:
2018-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficiency and safety of adding nimotuzumab to neoadjuvant and concurrent chemoradiotherapy in the treatment of patients with locoregionally advanced squamous cell carcinoma of the oropharynx and hypopharynx.

Phase:

Phase 2

Details

Lead Sponsor:

The Second People's Hospital of Sichuan

Collaborator:

Biotech Pharmaceutical Co., Ltd.

Treatments:

Cisplatin
Docetaxel
Nimotuzumab